checkAd
    Startseite > Aktien > Astria Therapeutics > Nachrichten
    Astria Therapeutics
    Aktie
    ISIN: US04635X1028 WKN: A3C2EY SYM: ATXS Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    8,8300
     
    USD
    -3,50 %
    -0,3200 USD
    Letzter Kurs 02:00:00 Nasdaq
    Geldkurs
    17.06.24
    8,8300
     
    USD
    1.400 STK
    Briefkurs
    17.06.24
    8,8500
     
    USD
    1.200 STK

    Astria Therapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.06.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
    30.05.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
    24.05.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
    23.05.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
    09.05.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
    08.05.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    02.05.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
    09.04.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    03.04.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
    25.03.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.03.24 · Business Wire (engl.) · Astria Therapeutics
    Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
    04.03.24 · Business Wire (engl.) · Astria Therapeutics